JP2007524686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007524686A5 JP2007524686A5 JP2006553352A JP2006553352A JP2007524686A5 JP 2007524686 A5 JP2007524686 A5 JP 2007524686A5 JP 2006553352 A JP2006553352 A JP 2006553352A JP 2006553352 A JP2006553352 A JP 2006553352A JP 2007524686 A5 JP2007524686 A5 JP 2007524686A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen
- immunotoxin
- variable domain
- immunoglobulin variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002596 immunotoxin Substances 0.000 claims 21
- 230000002637 immunotoxin Effects 0.000 claims 21
- 231100000608 immunotoxin Toxicity 0.000 claims 21
- 229940051026 immunotoxin Drugs 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108060003951 Immunoglobulin Proteins 0.000 claims 15
- 102000018358 immunoglobulin Human genes 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- 108010083644 Ribonucleases Proteins 0.000 claims 8
- 102000006382 Ribonucleases Human genes 0.000 claims 8
- 230000004927 fusion Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 3
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 3
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- -1 P1GF Proteins 0.000 claims 2
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims 1
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims 1
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 1
- 101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 102100022497 Mucin-3A Human genes 0.000 claims 1
- 102100022693 Mucin-4 Human genes 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54422704P | 2004-02-13 | 2004-02-13 | |
| US60/544,227 | 2004-02-13 | ||
| PCT/US2005/004860 WO2005080586A1 (en) | 2004-02-13 | 2005-02-14 | Fusion proteins containing recombinant cytotoxic rnases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116401A Division JP2012197286A (ja) | 2004-02-13 | 2012-05-22 | 組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007524686A JP2007524686A (ja) | 2007-08-30 |
| JP2007524686A5 true JP2007524686A5 (enExample) | 2008-04-03 |
| JP5150103B2 JP5150103B2 (ja) | 2013-02-20 |
Family
ID=34886009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553352A Expired - Fee Related JP5150103B2 (ja) | 2004-02-13 | 2005-02-14 | 組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質 |
| JP2012116401A Pending JP2012197286A (ja) | 2004-02-13 | 2012-05-22 | 組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116401A Pending JP2012197286A (ja) | 2004-02-13 | 2012-05-22 | 組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7544487B2 (enExample) |
| EP (1) | EP1720996A4 (enExample) |
| JP (2) | JP5150103B2 (enExample) |
| AU (1) | AU2005214361B2 (enExample) |
| CA (1) | CA2555661C (enExample) |
| WO (1) | WO2005080586A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| AU2005214361B2 (en) * | 2004-02-13 | 2011-03-24 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
| US8551480B2 (en) * | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
| ATE547123T1 (de) * | 2006-04-21 | 2012-03-15 | Mab Factory Gmbh | Antikörper-rnase-konjugat |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| HRP20230487T1 (hr) | 2009-02-13 | 2023-07-21 | Immunomedics, Inc. | Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti |
| JP6114936B2 (ja) * | 2009-08-31 | 2017-04-19 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 強力な細胞毒性活性を示すランピルナーゼ（ｒａｐ）を含む免疫毒素の組成物及び使用方法 |
| AU2013203097B2 (en) * | 2009-11-02 | 2016-01-14 | University Of Washington | Therapeutic nuclease compositions and methods |
| WO2011053982A2 (en) | 2009-11-02 | 2011-05-05 | University Of Washington | Therapeutic nuclease compositions and methods |
| CA2808211C (en) * | 2010-08-17 | 2018-08-28 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| US8518399B2 (en) * | 2010-11-17 | 2013-08-27 | Tamir Biotechnology, Inc. | Methods of treating infections originating from viruses in the herpesviridae family |
| JP6063450B2 (ja) | 2011-04-29 | 2017-01-18 | ユニヴァーシティ オブ ワシントン | 治療用ヌクレアーゼ組成物および方法 |
| CN116063522A (zh) * | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| US8663964B2 (en) * | 2011-07-20 | 2014-03-04 | Tamir Biotechnology, Inc. | Methods of treating human papillomavirus |
| PL2900277T3 (pl) | 2012-12-13 | 2022-05-16 | Immunomedics, Inc. | Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności |
| HRP20192080T1 (hr) | 2013-10-31 | 2020-02-07 | Resolve Therapeutics, Llc | Terapeutske fuzije nukleaza-albumine i postupci |
| US9919034B2 (en) | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
| BR112016022214A2 (pt) * | 2014-03-28 | 2017-10-24 | Tamir Biotechnology Inc | rnase para uso no tratamento ou prevenção de infecções virais |
| US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
| AU2015328370B2 (en) | 2014-10-07 | 2021-08-05 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| CN104622903B (zh) * | 2015-01-20 | 2018-10-09 | 奥思达干细胞有限公司 | 抗恶性黑色素瘤的干细胞制剂及其制备方法 |
| EP3307238A1 (en) * | 2015-06-15 | 2018-04-18 | Tamir Biotechnology, Inc. | Pharmaceuticals for treatment of viral infections of the eye |
| PT3313443T (pt) | 2015-06-25 | 2023-08-30 | Immunomedics Inc | Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| WO2017142807A1 (en) | 2016-02-16 | 2017-08-24 | Tamir Biotechnology, Inc. | Treatment or prevention of zika virus infections by administration of a ribonuclease |
| CN107513107B (zh) * | 2016-06-15 | 2022-03-15 | 上海南方模式生物科技股份有限公司 | 抗肿瘤融合蛋白及其制法和应用 |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| JP7374091B2 (ja) | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | 可溶性インターフェロン受容体およびその使用 |
| KR102118635B1 (ko) * | 2017-12-28 | 2020-06-04 | 오름테라퓨틱 주식회사 | 세포질 침투 항체에 융합된 rna 분해효소를 포함하는 면역독소 |
| CN116718765B (zh) * | 2023-06-15 | 2025-07-29 | 中牧实业股份有限公司 | 一种牛结节性皮肤病阻断elisa抗体检测试剂盒及其应用 |
| CN117281774B (zh) * | 2023-11-24 | 2024-02-09 | 潍坊医学院 | 基于抑制肿瘤cox-2和cxcr4的共载脂质纳米胶束及制备方法 |
| CN120424884B (zh) * | 2025-07-10 | 2025-11-04 | 上海惠盾因泰生物科技有限公司 | 表达分泌型il-2融合蛋白的工程化til及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US6395276B1 (en) * | 1997-05-02 | 2002-05-28 | Immunomedics, Inc. | Immunotoxins directed against malignant cells |
| US6653104B2 (en) * | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US6090381A (en) * | 1997-02-11 | 2000-07-18 | Immunomedics, Inc. | Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope |
| US6045793A (en) * | 1997-02-19 | 2000-04-04 | Us Health | Recombinant ribonuclease proteins |
| ATE297996T1 (de) * | 1998-03-11 | 2005-07-15 | Immunomedics Inc | Rekombinante onconase und fusionsproteine davon |
| US20030099629A1 (en) * | 1999-03-11 | 2003-05-29 | Immunomedics, Inc. | Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase |
| ES2871905T3 (es) * | 2002-03-01 | 2021-11-02 | Immunomedics Inc | Inmunoconjugado que comprende anticuerpos de RS7 humanizados |
| KR101115797B1 (ko) * | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법 |
| AU2005214361B2 (en) * | 2004-02-13 | 2011-03-24 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
-
2005
- 2005-02-14 AU AU2005214361A patent/AU2005214361B2/en not_active Ceased
- 2005-02-14 US US11/056,182 patent/US7544487B2/en not_active Expired - Fee Related
- 2005-02-14 EP EP05723127A patent/EP1720996A4/en not_active Withdrawn
- 2005-02-14 JP JP2006553352A patent/JP5150103B2/ja not_active Expired - Fee Related
- 2005-02-14 WO PCT/US2005/004860 patent/WO2005080586A1/en not_active Ceased
- 2005-02-14 CA CA2555661A patent/CA2555661C/en not_active Expired - Fee Related
-
2009
- 2009-06-05 US US12/479,250 patent/US8192739B2/en not_active Expired - Fee Related
-
2012
- 2012-02-22 US US13/402,480 patent/US9745374B2/en not_active Expired - Fee Related
- 2012-05-22 JP JP2012116401A patent/JP2012197286A/ja active Pending
-
2017
- 2017-08-02 US US15/666,902 patent/US20170334996A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007524686A5 (enExample) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| Labrijn et al. | Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange | |
| Fan et al. | Bispecific antibodies and their applications | |
| US10494446B2 (en) | Readily isolated bispecific antibodies with native immunoglobulin format | |
| Wang et al. | Silencing Fc domains in T cell–engaging bispecific antibodies improves T-cell trafficking and antitumor potency | |
| CN106459213B (zh) | 修饰的j链 | |
| JP6205363B2 (ja) | ハイブリッド定常領域 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2021502104A5 (enExample) | ||
| JP2009502171A5 (enExample) | ||
| Yu et al. | A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma | |
| JP2009517337A5 (enExample) | ||
| US20100143356A1 (en) | Therapeutic and diagnostic anti-hsp70 antibodies | |
| Yang et al. | Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members | |
| JP2012523848A5 (enExample) | ||
| TW202200618A (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2022504826A (ja) | ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 | |
| TWI690539B (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| Boje et al. | Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers | |
| Sugiyama et al. | A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity | |
| Hollander | Bispecific antibodies for cancer therapy | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| JPWO2020252366A5 (enExample) |